Skip to Main Content

Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Conditions

Immune System

What is the purpose of this trial?

Brief Summary:

A long-term observational registry in patients with atopic dermatitis initiating treatment with DUPIXENT® (dupilumab)

  • Trial with
    Regeneron Pharmaceuticals, Inc.
  • Start Date
    07/15/2019
  • End Date
    12/01/2023
Trial Image

For more information about this study, contact:

Mahin Dawood

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/23/2019
  • Study HIC
    #2000023360